HBV infection persistently activates the NF-kB pathway, leading to the upregulation of multidrug resistance gene expression in hepatocellular carcinoma cells, resulting in reduced sensitivity to a variety of chemotherapeutic agents (21, 22). This evidence concerns the gene NFKB1 and hepatocellular carcinoma.